Kaminski, Rafal M.
UCB Pharma (Belgium)
3 papers on CoChatORCID 0000-0002-1632-4101
Most cited papers
- Verified
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs
Epilepsy research and treatmentNeuroscience and Neuropharmacology Research
Cited by 184
- Verified
Brivaracetam: Rationale for discovery and preclinical profile of a selective SV 2A ligand for epilepsy treatment
Klitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia
Epilepsy research and treatmentPharmacological Effects and Toxicity Studies
Cited by 168
- Verified
GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors
Mullier, B., Wolff, C., Sands, Z. A., Ghisdal, P., Muglia, P., Kaminski, R. M., & André, V. M. (2017) · Neuropharmacology
Neuroscience and Neuropharmacology ResearchEpilepsy research and treatment
Cited by 65
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free